Personalized Dosing Helped Control Seizures In An Infant

What was studied

This report describes one infant with global developmental delay and refractory epilepsy associated with a TBC1D24 mutation. The infant had uncontrolled seizures despite taking multiple antiseizure drugs.

Doctors found that serum levels of valproic acid, carbamazepine, and phenytoin were subtherapeutic. They then used pharmacokinetic simulations, by numerically solving ordinary differential equations, to help optimize dosing.

What they found

After the simulation-guided dose changes, valproate was modified to 240 mg every 4 hours and carbamazepine to 100 mg three times a day. Follow-up serum drug levels were within the therapeutic range, and the infant had no further seizure episodes in the report. The authors present this case as highlighting the potential value of individualized pharmacokinetic simulation for dose optimization instead of empirical dose adjustments.

Limits of the evidence

This was only a single case report, so it cannot show that this approach works for most children. There was no comparison group, and the abstract does not say how long the infant remained seizure-free. Because multiple antiseizure drugs were involved, it is also hard to know exactly which changes were most important. The abstract also gives limited detail about side effects, long-term outcomes, and how well this method would apply to other children.

For families and caregivers

For families, this report suggests that when seizures remain uncontrolled and medicine blood levels are low, blood test monitoring and individualized pharmacokinetic modeling may sometimes help doctors adjust doses. It also shows why drug level monitoring can matter for medicines with a narrow therapeutic index. Still, this is evidence from one child, so it should not be taken as proof that the same method will help every child with epilepsy.

What to watch next

More evidence would come from studies in more children that compare simulation-guided dosing with usual dose adjustment and track seizure control and side effects over time.

Terms in this summary

refractory epilepsy

Epilepsy in which seizures continue despite treatment with antiseizure medicines.

therapeutic drug monitoring

Measuring medicine levels in the blood to help adjust the dose.

therapeutic range

The blood level range where a medicine is expected to be effective without being too high.

pharmacokinetic

About how the body handles a medicine over time.

ordinary differential equations

A type of math used in computer models to predict how things change over time, such as drug levels in the body.

subtherapeutic

Too low to be in the usual treatment range.

empirical dose adjustment

Changing a dose based mainly on observation and experience rather than a personalized model.

TBC1D24 mutation

A change in the TBC1D24 gene; in this report, the infant had a TBC1D24 mutation along with global developmental delay and epilepsy.